Certainly not suggesting we increase our current out goings, but...

Certainly not suggesting we increase our current out goings, but I’d ask the question whether PAR is adequately resourced to meet its self imposed deadlines? Is a lack of resources the reason we can’t meet our submission deadlines and if so I’d much rather we invest in our team and hit those targets rather than spend on overseas roadshows. Clearly the science speaks for itself, and clearly our attempts at self promotion overseas has failed dismally (refer share register and refer pharma of any size showing interest at this stage). All that matters is that the FDA receives quality data and as a shareholder, that the data is delivered as expeditiously as possible…nothing else matters…just FDA approval….the rest will take care of itself and in my opinion pointless spending money anywhere else…